Ngalaba Mba Nile

Na 20 Ọgọst 2025, Abbisko Therapeutics kwupụtara na Center forDrug Evaluation (CDE) nke China National Medical Products Administration (NlPA) ekpebiela itinye akwụkwọ maka ọgwụ mgbochi PD-1 nke Abbisko, ABSK043, yana Shanghai Alist Pharmaceuticals KRAS ...GỤKWUO»

N'oge na-adịbeghị anya, ọmụmụ Antengene's Phase I/II CLINCH nke ATG-022 (CLDN18.2 antibody-drug conjugate), onye agadi nwere ọrịa kansa afọ dị elu nke nwere ọtụtụ usoro chemotherapy, immunotherapy na ọgwụgwọ ezubere iche n'agbanyeghị nnukwu metastases nwetara nzaghachi zuru oke (CR) mgbe e mesịrị ...GỤKWUO»

Na Ọgọst 13, 2025, Pacific Time, webụsaịtị gọọmentị nke 2025 World Conference on Lung Cancer (WCLC) wepụtara nchịkọta nyocha ahọpụtara maka ogbako nke afọ a. Otu n'ime ihe ndị kacha pụta ìhè bụ nchịkọta emelitere maka nnwale ahụike nke mbụ n'ime mmadụ nke HLX43, Henlius' PD-L1 ADC. A...GỤKWUO»

Na ụbọchị asaa nke ọnwa Ọgọstụ, Center for Drug Evaluation (CDE) nke National Medical Products Administration (NMPA) kwupụtara na atụọla aro ka a tinye ọgwụ PA3-17 n'ime nhazi ọgwụgwọ ọhụrụ, nke e mere maka ọgwụgwọ ndị okenye nwere ọrịa T-cell acute lymph...GỤKWUO»

Na ụbọchị iri na otu nke ọnwa Ọgọst, Center for Drug Evaluation (CDE) nke National Medical Products Administration (NMPA) gosiri na a tụrụ aro ka InxMed tinye ọgwụ IN10018 maka nhazi ọgwụgwọ ọhụrụ, nke e mere maka ijikọta ya na D-1553 iji gwọọ KRA dị elu ma ọ bụ nke metastatic n'ógbè ahụ...GỤKWUO»

Maazị X bụ onye ọrịa dị afọ iri anọ na ụma nke a chọpụtara na ọ nwere acral melanoma. Mgbe a wachara ya ahụ nke ọma mgbe a chọpụtara ya na 2015, ọnọdụ ya kwụsiri ike ruo afọ itoolu. N'ụzọ dị mwute, ihe dị ka otu afọ gara aga, ọrịa ya malitere ọzọ na mpụta nke nje ngụgụ abụọ ahụ. N'agbanyeghị na ọ nwetara inguinal na pelvic l...GỤKWUO»

Na Julaị 31, AstraZeneca na Merck & Co. jikọrọ aka kwupụta na a kwadoro ọgwụ mgbochi PARP ha bụ Lynparza, yana Abiraterone na prednisolone, na China maka ọgwụgwọ ndị okenye nwere ọrịa kansa prostate na-eguzogide castration (mCRPC) ndị nwere germline ma ọ bụ ụfọdụ...GỤKWUO»

Na Julaị 31, 2025, ImmuneOnco Biopharmaceuticals kwupụtara data nchekwa na arụmọrụ mbụ site na ọmụmụ ihe mepere emepe nke Phase 2 nke IMM2510 na njikọta ya na kemoterapi maka ndị ọrịa nọ n'ihu nwere kansa akpa ume nke na-abụghị obere mkpụrụ ndụ (NSCLC) emere na China. Dịka ọ dị na Julaị 1, 2025,...GỤKWUO»

Na Julaị 30, National Medical Products Administration (NMPA) kwadoro ahịa HICARA maka ọgwụgwọ nke ndị okenye nwere lymphoma B-cell buru ibu nke na-alaghachi azụ ma ọ bụ nke na-adịghị agbanwe agbanwe (r/r LBCL) bụ ndị natara usoro ọgwụgwọ sistemụ abụọ ma ọ bụ karịa. Nke a gụnyere nnukwu B-cell nke na-agbasa ...GỤKWUO»

N'oge na-adịbeghị anya, otu onye ọrịa nwere ọrịa kansa pancreas dị elu nke dara ọtụtụ usoro ọgwụgwọ gara aga nwetara mbelata etuto ahụ mgbe ọ natara ọgwụgwọ mkpụrụ ndụ CAR-T KD-496, ebe a na-ahụ na a na-ebelata ya ruo ụbọchị 180 mgbe ọgwụgwọ gasịrị. Ugbu a, enwere ọtụtụ nnwale ahụike nke ọrịa ọhụrụ...GỤKWUO»

Na Julaị 16, akwụkwọ akụkọ mba ụwa kachasị elu bụ Nature Medicine bipụtara data nyocha na SHR-A1904, ọgwụ mgbochi-ọgwụ conjugate (ADC) nke na-elekwasị anya na claudin 18.2 (CLDN18.2), maka ọgwụgwọ nke kansa afọ ma ọ bụ kansa gastroesophageal junction (GC/GEJC). Ndị nchọpụta ahụ mere nyocha mbụ n'ime...GỤKWUO»

Julaị 17, 2025 – Innovent Biologics kwupụtara na Nature Medicine ebipụtala nsonaazụ nke ọmụmụ ahụike nke Phase 1 nke IBI343, ọgwụ mgbochi CLDN18.2 ADC ọhụrụ, maka ọgwụgwọ nke adenocarcinoma afọ na-aga n'ihu na gastric/gastroesophageal junction (G/GEJ). Mbipụta na mba ụwa a bụ isi...GỤKWUO»